Exhibit 99.01

The Private Securities Litigation Reform Act of 1995, as amended (the "Act"),
provides a "safe harbor" for "forward-looking statements" (as defined in the
Act). The Company's filings with the Securities and Exchange Commission (the
"SEC"), including its Annual Report on Form 10-K, Annual Report to Shareholders,
Forms 10-Q and Forms 8-K (along with any exhibits to such filings as well as any
amendments to such filings), press releases, other written or oral statements
made by or on behalf of the Company, may include, reference or incorporate by
reference forward-looking statements which reflect the Company's current view
(as of the date such forward-looking statement is made) with respect to future
events, prospects, projections and/or financial performance. These
forward-looking statements are subject to various risks and uncertainties that
could cause actual results to differ materially from those contemplated,
projected, anticipated or implied by these forward-looking statements. These
risks and uncertainties include, but are not limited to:

- -     uncertainties relating to general economic, political, business, industry,
      regulatory and market conditions;

- -     the loss of one or more key customer or supplier relationships, such as
      pharmaceutical and medical/surgical manufacturers for which alternative
      supplies may not be available or easily replaceable, or unfavorable
      changes to the terms of those relationships, or changes in customer mix;

- -     changes in manufacturers' pricing, selling, inventory, distribution or
      supply policies or practices, including policies concerning price
      inflation;

- -     uncertainties related to the timing, negotiation and likelihood of success
      of the Company's Pharmaceutical Distribution business model transition
      with respect to how the Company is compensated for the logistical, capital
      and administrative services that it provides to pharmaceutical
      manufacturers, and the continued dependence until such transition is
      completed, if ever, upon pharmaceutical price inflation, which price
      inflation is often unpredictable;

- -     changes in the distribution or outsourcing pattern for pharmaceutical and
      medical/surgical products and services, including an increase in direct
      distribution or a decrease in contract packaging by pharmaceutical
      manufacturers;

- -     potential liabilities associated with warranties of the Company's
      information systems, and the malfunction or failure of the Company's
      information systems or those of third parties with whom the Company do
      business, such as malfunctions or failures associated with date-related
      issues, incompatible software, improper coding and disruption to
      internet-related operations;

- -     the costs, difficulties, and uncertainties related to the integration of
      recently acquired businesses, including liabilities related to the
      operations or activities of such businesses prior to their acquisition;

- -     changes to the presentation of financial results and position resulting
      from adoption of new accounting principles or upon the advice of the
      Company's independent accountants or the staff of the SEC;

- -     weaknesses in internal controls and procedures under Section 404 of the
      Sarbanes-Oxley Act of 2002;

- -     difficulties and costs associated with enhancing the Company's accounting
      systems and internal controls and complying with financial reporting
      requirements;

- -     changes in government regulations or the Company's failure to comply
      with those regulations or other applicable laws;



- -     the results, effects or timing of any inquiry or investigation by any
      regulatory authority and any related legal and administrative proceedings,
      which may include the institution of administrative, civil injunctive or
      criminal proceedings against the Company and/or current or former Company
      officers or employees, the imposition of fines and penalties, suspensions
      or debarments from government contracting, and/or other remedies and
      sanctions;

- -     the costs and effects of commercial disputes, shareholder claims,
      derivative claims or other legal proceedings;

- -     downgrades of the Company's credit ratings, and the potential that such
      downgrades could negatively impact the Company's access to capital;

- -     increased costs for the raw materials used by the Company's manufacturing
      businesses or shortages in these raw materials;

- -     the risks of counterfeit products in the supply chain;

- -     the possible adverse effects on the Company of the importation of
      pharmaceuticals and/or other health care products;

- -     injury to person or property resulting from the Company's manufacturing,
      packaging, repackaging, drug delivery system development and
      manufacturing, information systems, or pharmacy management services;

- -     competitive factors in the Company's healthcare service businesses,
      including pricing pressures;

- -     unforeseen changes in the Company's existing agency and distribution
      arrangements;

- -     the continued financial viability and success of the Company's customers,
      suppliers, and franchisees;

- -     difficulties encountered by the Company's competitors, whether or not the
      Company faces the same or similar issues;

- -     technological developments and products offered by competitors;

- -     failure to retain or continue to attract senior management or key
      personnel;

- -     uncertainties related to transitions in senior management positions;

- -     risks associated with international operations, including fluctuations in
      currency exchange ratios;

- -     costs associated with protecting the Company's trade secrets and enforcing
      its patent, copyright and trademark rights, and successful challenges to
      the validity of its patents, copyrights or trademarks;

- -     difficulties or delays in the development, production, manufacturing, and
      marketing of new products and services, including difficulties or delays
      associated with obtaining requisite regulatory consents or approvals
      associated with those activities;

- -     strikes or other labor disruptions;

- -     labor, pension and employee benefit costs;

- -     changes in hospital buying groups or hospital buying practices; and

- -     other factors described in the Company's Annual Report on Form 10-K or
      Quarterly Reports on Form 10-Q or the other documents the Company files
      with the SEC including, but not limited to the section entitled "Risk
      Factors That May Affect Future Results" in the Company's Annual Report on
      Form 10-K.

The words "believe," "expect," "anticipate," "project," and similar expressions
generally identify "forward-looking statements," which speak only as of the date
the statement was made. The Company undertakes no obligation (nor does it
intend) to publicly update or revise any forward-looking statements, whether as
a result of new information, future events or otherwise, except to the extent
required under applicable law.